候选基因多态性和力量运动员的地位:一个元分析方法
Gökhan İpekoğlu1, Tuğba Çetin2, Tülay Sırtbaş1
1Faculty of Sport Science, Ordu University, Ordu, Turkey.
Journal of physiology and biochemistry
|March 7, 2025
概括
某些遗传变异,如GALNTL6 rs558129和NOS3 rs2070744,与力量运动员的地位有关. 这些遗传多态可能作为识别运动潜力的重要标记.
科学领域:
- 运动科学 运动科学 运动科学
- 遗传学 遗传学 是一个
- 人体生理学 人体生理学
背景情况:
- 运动员的地位受到包括遗传在内的各种因素的影响.
- 识别与运动表现相关的遗传标记是正在进行的研究领域.
研究的目的:
- 进行一项元分析,调查运动员身份与特定候选人遗传多态度之间的关联.
- 与对照组相比,评估力量运动员中选定的遗传变异的流行率.
主要方法:
- 2009年至2022年间发表的23项病例控制研究的元分析.
- 来自PubMed和Web of Science数据库的数据来源.
- 使用随机或固定效应模型进行分析,评估赔率比率和置信区间.
主要成果:
- 在力量运动员中,GALNTL6 rs558129 T/T基因型,MCT1 rs1049434 T/T基因型和NOS3 rs2070744 T等位基因/基因型更为普遍.
- 相反,在对照组中,GALNTL6 rs558129 C等位基因/基因型和AGTR2 rs11091046 C等位基因/基因型更常见.
- 对于这些关联,观察到统计学意义 (p < 0.05).
结论:
- 特定的遗传多态,包括GALNTL6 rs558129,MCT1 rs1049434和NOS3 rs2070744,显示出与力量运动员地位的显著关联.
- 这些发现表明,某些遗传标记可能有价值,用于识别有能力运动倾向的个体.
- 需要进一步的研究来验证和扩展这些在运动群体中的遗传关联.
更多相关视频
相关概念视频
01:05Single Nucleotide Polymorphisms-SNPs
14.8K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.8K
01:27Principles of Pharmacogenetics: Types of Genetic Variants
143
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
143
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
01:27Pharmacogenetics of Drug Metabolism: Overview
195
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
195
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129